Two Sigma Investments LP Acquires 231,579 Shares of Haemonetics Co. (NYSE:HAE)

Two Sigma Investments LP grew its holdings in Haemonetics Co. (NYSE:HAE) by 1,861.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 244,023 shares of the medical instruments supplier’s stock after acquiring an additional 231,579 shares during the period. Two Sigma Investments LP owned 0.46% of Haemonetics worth $14,173,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in HAE. Meeder Asset Management Inc. raised its position in Haemonetics by 2,845.3% in the fourth quarter. Meeder Asset Management Inc. now owns 1,885 shares of the medical instruments supplier’s stock worth $110,000 after acquiring an additional 1,821 shares during the period. CIBC Asset Management Inc bought a new position in Haemonetics in the fourth quarter worth approximately $210,000. Everence Capital Management Inc. bought a new position in Haemonetics in the fourth quarter worth approximately $212,000. First Allied Advisory Services Inc. bought a new position in Haemonetics in the fourth quarter worth approximately $220,000. Finally, Dean Capital Investments Management LLC bought a new position in Haemonetics in the fourth quarter worth approximately $246,000.

How to Become a New Pot Stock Millionaire

Several research firms have weighed in on HAE. Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Jefferies Group reiterated a “buy” rating and issued a $80.00 price target on shares of Haemonetics in a research report on Wednesday, February 7th. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Tuesday, February 6th. ValuEngine raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Barrington Research reissued an “outperform” rating and issued a $71.00 price objective (up from $57.00) on shares of Haemonetics in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $71.33.

In related news, EVP Michelle L. Basil sold 389 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $72.23, for a total transaction of $28,097.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

Shares of NYSE HAE traded down $1.27 during midday trading on Friday, reaching $71.53. The stock had a trading volume of 554,164 shares, compared to its average volume of 421,297. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.33. The stock has a market cap of $3,823.14, a PE ratio of 46.75, a price-to-earnings-growth ratio of 3.09 and a beta of 0.89. Haemonetics Co. has a 12-month low of $38.47 and a 12-month high of $75.45.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.18. The firm had revenue of $234.04 million during the quarter, compared to analysts’ expectations of $227.79 million. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. research analysts expect that Haemonetics Co. will post 1.86 EPS for the current year.

Haemonetics declared that its board has authorized a stock buyback plan on Tuesday, February 6th that authorizes the company to buyback $260.00 million in shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/haemonetics-co-hae-position-lifted-by-two-sigma-investments-lp.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply